# The Effect of LY333531 on Protein in the Urine in Patients With Type 2 Diabetes

> **NCT00044148** · PHASE2 · COMPLETED · sponsor: **Chromaderm, Inc.**

## Conditions studied

- Diabetic Nephropathy

## Interventions

- **DRUG:** LY333531

## Key facts

- **NCT ID:** NCT00044148
- **Lead sponsor:** Chromaderm, Inc.
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2002-07-16
- **Primary completion:** 2004-04-28
- **Final completion:** 2004-04-28
- **Target enrollment:** — (—)
- **Last updated:** 2017-02-01


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT00044148

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT00044148, "The Effect of LY333531 on Protein in the Urine in Patients With Type 2 Diabetes". Retrieved via AI Analytics 2026-06-08 from https://api.ai-analytics.org/clinical/NCT00044148. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*